Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL SUSPENSIONGeneric

ABACAVIR AND LAMIVUDINE

ABACAVIR;LAMIVUDINE

Standard Dose
120MG;60MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview ABACAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 204915 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR;LAMIVUDINE Form and strength TABLET; ORAL SUSPENSION - 120MG;60MG Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2014-10-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR AND LAMIVUDINE is listed in Drugs@FDA under application 204915 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR;LAMIVUDINE Form and strength TABLET; ORAL SUSPENSION - 120MG;60MG Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2014-10-23 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ABACAVIR AND LAMIVUDINE (ABACAVIR;LAMIVUDINE) | Drug Monograph | MedicHelpline